Active surveillance with or without a 6 months Apalutamide treatment in low risk prostate cancer: a phase II randomized multicenter trial.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PC-ARN
- 31 Aug 2018 Biomarkers information updated
- 15 Mar 2018 Last checked against European Clinical Trials Database record.
- 02 May 2017 Planned End Date changed from 27 Mar 2022 to 28 Apr 2022.